All In Biotech

NDA 214938 · Biomarin Pharm

Voxzogo

Vosoritide · Subcutaneous

NovelAccelerated approvalOrphan

CDER novel approval, Nov 19, 2021: To improve growth in children five years of age and older with achondroplasia and open epiphyses

Last checked: Nov 19, 2026Latest source record: Nov 4, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Nov 19, 2021

Approved uses

2

Original approval plus efficacy supplements

Registered trials

17

5 Phase 3, 3 recruiting

FAERS reports

1

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 25, 2025.

VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). VOXZOGO is a C type natriuretic peptide (CNP) analog indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1 )

Mechanism: In patients with achondroplasia, endochondral bone growth is negatively regulated due to a gain of function mutation in fibroblast growth factor receptor 3 ( FGFR3 ). Binding of vosoritide to natriuretic peptide receptor-B (NPR-B) antagonizes FGFR3 downstream signaling by inhibiting the extracellular signal-regulated kinases 1 and 2 (ERK1/2) in the mitogen-activated protein kinase (MAPK) pathway at the level of rapidly accelerating fibrosarcoma serine/threonine protein kinase (RAF-1). As a result, vosoritide, like CNP, acts as a positive regulator of endochondral bone growth as it promotes...

Therapeutic areas: Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 20, 2023 Supplement 2 · Efficacy OrphanLabelLetterReview
  • Nov 19, 2021 Original approval · Type 1 - New Molecular Entity NovelAccelerated approvalOrphanLabelLetterReview
3 products under this application
  • VOXZOGO · VOSORITIDE 0.56MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • VOXZOGO · VOSORITIDE 1.2MG/VIAL · POWDER, SUBCUTANEOUS · Prescription
  • VOXZOGO · VOSORITIDE 0.4MG/VIAL · POWDER, SUBCUTANEOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Vosoritide" as an intervention, any sponsor and status, largest first.

All 17 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dose calculation error1
  • product preparation error1
  • product prescribing error1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 15 on PubMed

Sponsor: BioMarin

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.